Ocuphire Pharma (NASDAQ:OCUP – Free Report) had its price target decreased by Canaccord Genuity Group from $18.00 to $10.00 in a research report report published on Wednesday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.
Separately, HC Wainwright decreased their target price on Ocuphire Pharma from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th.
Check Out Our Latest Stock Report on Ocuphire Pharma
Ocuphire Pharma Stock Performance
Ocuphire Pharma (NASDAQ:OCUP – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01). The firm had revenue of $1.11 million during the quarter, compared to the consensus estimate of $1.80 million. Ocuphire Pharma had a negative return on equity of 30.19% and a negative net margin of 85.75%. Equities research analysts expect that Ocuphire Pharma will post -1.11 EPS for the current year.
Institutional Trading of Ocuphire Pharma
Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in shares of Ocuphire Pharma in the first quarter worth about $36,000. Empowered Funds LLC purchased a new position in Ocuphire Pharma during the 1st quarter valued at approximately $74,000. Finally, Vanguard Group Inc. increased its stake in Ocuphire Pharma by 6.9% in the 1st quarter. Vanguard Group Inc. now owns 992,200 shares of the company’s stock worth $1,994,000 after acquiring an additional 64,400 shares during the last quarter. Hedge funds and other institutional investors own 14.97% of the company’s stock.
Ocuphire Pharma Company Profile
Ocuphire Pharma, Inc, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.
Further Reading
- Five stocks we like better than Ocuphire Pharma
- Stock Average Calculator
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Health Care Stocks Explained: Why You Might Want to Invest
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with MarketBeat.com's FREE daily email newsletter.